In fact, we have recently demonstrated that genetic deletion or pharmacological blockade of KPTCs CB1R ameliorates diabetes-induced renal dysfunction, inflammation, and fibrosis, which goes hand in hand with GLUT2 downregulation [36,37]. This evidence concerns the gene SLC2A2 and diabetes mellitus.